Novavax Management
Management criteria checks 2/4
Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 2.08 years. total yearly compensation is $7.30M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.057% of the company’s shares, worth €770.00K. The average tenure of the management team and the board of directors is 2 years and 4.5 years respectively.
Key information
John Jacobs
Chief executive officer
US$7.3m
Total compensation
| CEO salary percentage | 9.1% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2yrs |
| Board average tenure | 4.5yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$285m |
| Jun 30 2024 | n/a | n/a | -US$294m |
| Mar 31 2024 | n/a | n/a | -US$399m |
| Dec 31 2023 | US$7m | US$663k | -US$545m |
Compensation vs Market: John's total compensation ($USD7.30M) is above average for companies of similar size in the Austrian market ($USD1.88M).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Jacobs (57 yo)
2.1yrs
Tenure
US$7,301,009
Compensation
Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$7.30m | 0.057% € 770.0k | |
| President & COO | 1.3yrs | US$1.88m | 0.018% € 237.3k | |
| Executive VP | 3.5yrs | US$1.50m | 0.020% € 273.3k | |
| Executive VP | 1.2yrs | US$1.53m | no data | |
| Executive VP & COO | 2.1yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Associate Director of Investor & Public Relations | 6.8yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | 1.6yrs | no data | no data | |
| Executive VP and Chief Corporate Affairs & Advocacy Officer | 3.1yrs | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | no data | |
| Executive VP & Chief Strategy Officer | 2yrs | no data | 0.0089% € 119.2k | |
| EVP and Head of Research & Development | less than a year | no data | no data |
2.0yrs
Average Tenure
59.5yo
Average Age
Experienced Management: NVAX's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$7.30m | 0.057% € 770.0k | |
| Independent Director | 4.7yrs | US$187.53k | 0.032% € 423.1k | |
| Independent Director | 15.1yrs | US$189.53k | 0.027% € 368.2k | |
| Independent Director | 4.2yrs | US$185.02k | 0.0065% € 87.8k | |
| Independent Director | 4.3yrs | US$175.28k | 0.0065% € 87.8k | |
| Independent Director | 6.3yrs | US$174.55k | 0.0092% € 123.8k | |
| Independent Director | 2.3yrs | US$191.78k | 0.0089% € 119.6k | |
| Independent Chairman of the Board | 14.8yrs | US$222.53k | 0.032% € 433.9k |
4.5yrs
Average Tenure
62yo
Average Age
Experienced Board: NVAX's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 19:09 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novavax, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| George Zavoico | B. Riley Securities, Inc. |